Pharmaceuticals

Filgrastim Biosimilars Market Forecast 2026–2030 Presenting Long-Term Industry Insights

April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Filgrastim Biosimilars Market Expected To Change From 2026 To 2030?

The filgrastim biosimilars market size has experienced substantial growth in recent years. It is projected to expand from $1.19 billion in 2025 to $1.33 billion in 2026, at a compound annual growth rate (CAGR) of 11.5%. This historical growth can be attributed to several factors including the high cost of originator filgrastim, the increasing prevalence of cancer and blood disorders, limited access to biologics in emerging regions, the development of hospital infrastructure, and early approvals of biosimilars by regulatory authorities.

The filgrastim biosimilars market size is projected to experience substantial growth in the coming years, with expectations to reach $2.09 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.9%. This expansion during the forecast period is primarily due to the introduction of next-generation filgrastim biosimilars, the broadening of contract manufacturing alliances, increasing adoption in chronic and autoimmune diseases, enhanced government support and reimbursement policies, and the development of patient-centric distribution and delivery systems. Significant trends anticipated for this period encompass the growing use of filgrastim biosimilars in oncology and blood disorder treatments, the expansion of contract manufacturing organizations for biosimilar production, a rise in the utilization of in-house vertically integrated manufacturing facilities, an increasing preference for hospital and retail pharmacy distribution channels, and a continued focus on cost-effective biologics along with improved access in emerging markets.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

What Key Factors Are Affecting The Filgrastim Biosimilars Market Demand?

The filgrastim biosimilars market is anticipated to expand due to the increasing occurrence of cancer. Cancer constitutes a collection of illnesses characterized by the uncontrolled proliferation and dissemination of atypical cells within the body, stemming from genetic alterations that interfere with normal cellular regulation. The growing incidence of cancer is partially attributable to population aging, as extended lifespans increase the probability of developing genetic mutations associated with the disease. Filgrastim biosimilars support cancer patients by stimulating the generation of white blood cells, thereby mitigating the danger of chemotherapy-induced neutropenia, and facilitating safer, uninterrupted cancer therapy. As an illustration, in October 2025, the UK’s National Health Service (NHS) reported 354,820 new cancer diagnoses in 2023, averaging 972 daily, marking an increase of 8,605 from 2022. Consequently, the increased rate of cancer is a key driver for the filgrastim biosimilars market.

Which Segment Types Are Examined In The Filgrastim Biosimilars Market Segment Study?

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

What Trends Are Influencing The Filgrastim Biosimilars Market?

Major companies operating in the filgrastim biosimilar market are focusing on creating novel products by utilizing sophisticated methods such as recombinant DNA technology for biosimilar production. This recombinant DNA technology entails forming hybrid or chimeric DNA through the insertion of an external genetic sequence into an organism’s DNA. As an illustration, in May 2023, Amneal Pharmaceuticals, a pharmaceutical firm based in the US, introduced FYLNETRA (pegfilgrastim-pbbk) in the United States, serving as a biosimilar alternative to Amgen’s NEULASTA, and prescribed for managing and preventing febrile neutropenia. This product facilitates the proliferation and differentiation of neutrophils derived from specific precursor cells, initiates their development, and enhances the endurance and performance of mature neutrophils, resulting in increases in neutrophil counts dependent on the dosage. The introduction of Fylnetra signifies a step forward in providing more accessible and economical medications, broadening availability for patients, healthcare providers, and insurers alike.

Which Players Are Part Of The Competitive Landscape Of The Filgrastim Biosimilars Market?

Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.

Get The Full Filgrastim Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Where Is The Filgrastim Biosimilars Market Primarily Concentrated By Region?

North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Filgrastim Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Browse Through More Reports Similar to the Global Filgrastim Biosimilars Market 2026, By The Business Research Company

Neutropenia Biologic Drug Treatments Market Report 2026

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

G Csf Market Report 2026

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Pegfilgrastim Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795